含有二硫尼尔化基组的两类块共聚物作为可见光响应药物载体,用于图像引导的输送
Lei Luo1, Fei Liu1, Zhiying Li1
1Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China.
Biomacromolecules
|February 14, 2024
概括
新的可见光响应纳米粒子提供向的癌症治疗. 这些纳米粒子使用四甲 (ZnTPP) 进行成像和药物释放,克服了传统光敏感系统的局限性.
科学领域:
- 生物材料科学 生物材料科学
- 纳米技术纳米技术
- 聚合物化学 聚合物化学
背景情况:
- 响应光的纳米粒子 (NP) 对药物输送具有前景,但通常使用短波长的光,限制组织透并引起细胞毒性.
- 现有的NP可能过于敏感,导致药物过早释放,效率降低和异常毒性.
研究的目的:
- 开发可见光响应的NP用于控制药物输送和癌症治疗术.
- 为了克服与短波长光响应系统相关的薄弱组织透和潜在细胞毒性的局限性.
主要方法:
- 合成的两类块共聚合物 (pDMA-ABSA) 与对可见光敏感的4-烯胺二硫酸 (ABSA) 和性N,N'-二甲基烯胺 (DMA) 单位.
- 装载有化疗药物达沙替尼和四甲 (ZnTPP) 作为成像剂和光敏感剂的NP.
- 通过ZnTPP介导的ABSA减小,可见光照射引发的研究NP干扰和药物释放.
主要成果:
- 证明了细胞内NP的实时光成像.
- 实现了对多个癌症细胞系的协同化学光动力学治疗.
- 通过将疏水性聚合物单元转化为疏水性聚合物单元,通过可见光触发的药物释放得到验证.
结论:
- 开发的可见光响应NP平台可实现精确的药物释放和治疗.
- 该系统绕过了传统光敏纳米系统的局限性,提供了更好的癌症治疗潜力.
- 这些NP显示了对先进的可控药物输送和癌症治疗术的前景.
相关概念视频
01:19Depolarizing Blockers: Pharmocokinetics
784
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
784
01:27Bioavailability Enhancement: Drug Permeability Enhancement
358
After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...
358
01:23Modified-Release Drug Delivery Systems: Classification
318
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
318
01:30Modified-Release Drug Delivery Systems: Stimuli-Activated
184
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also...
184
01:24Modified-Release Drug Delivery Systems: Site-Targeted
167
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
167
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
165
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
165